High-Risk Melanoma Patients More Likely to Receive Immunotherapy at End of Life
Metastatic melanoma patients at the highest risk of death are more likely than lower-risk patients to receive immunotherapy near the end of their life.
Megan Garlapow, PhD
Contributing Writer https://www.cancertherapyadvisor.com
Megan Garlapow, PhD, is the principal and owner of The Line Medical Communications, LLC. Garlapow has worked across a wide variety of projects and therapeutic areas. She holds a BA in biology from the University of Chicago and a PhD in genetics from North Carolina State University. Before working as a medical writer, Garlapow worked in a biopsychology lab, examining social factors affecting breast cancer in rats and people and in a neurogenetics lab, examining the circadian factors affecting nicotine addiction in a mouse model. In her PhD, she used quantitative genetics approaches to examine the regulation of feeding. Her postdoctoral research at Arizona State University focused on environmental and genetic factors affecting body weight. You can find her on LinkedIn at https://www.linkedin.com/in/megangarlapow/
